Company intelligence
ArcaScience
Patient centric AI company
About ArcaScience
ArcaScience is setting the new standard for Benefit–Risk Assessment, leveraging AI to turn clinical uncertainty into up to +5% approval success. Our AI-Benefit-Risk Solution is the first to be fully aligned with CIOMS and ICH guidelines, featuring: > Regulatory-ready: BRA exports are compliant with CIOMS/FDA/EMA, ready for submission to regulatory agencies > Full expert control: every AI-generated item can be reviewed, edited, and validated by the expert > Cross-functional collaboration: pharmacovigilance, clinical, regulatory, and medical affairs teams work on a single shared platform across the entire drug lifecycle > AI-powered synthesis: automated identification, extraction, and structuring of clinical and safety data > 100% sourced, no hallucination: full traceability on every data point The Impact: We reduce BRA timelines from 3–8 months to just 2–3 days, deliver +5% market access, and provide best-in-class candidate optimization both during and after clinical trials.
Verified activity
Signals from ArcaScience
4 published signals
Strategy & Corporate Development
ArcaScience sees the acquisition of Hugging Face by NVIDIA for $12.9 billion as a strategic move to build an open ecosystem across borders.
Reported by ArcaScience
Presence & Recognition
ArcaScience employee Romain Clement is speaking at Frontiers Health in Berlin from October 21-22.
Reported by ArcaScience
Presence & Recognition
ArcaScience is planning to attend events in London, Boston, Montréal, and Paris.
Reported by ArcaScience
Presence & Recognition
ArcaScience is attending the World Patient Safety Congress in Amsterdam from September 22 to 24, at Stand 10.606.
Reported by ArcaScience